SuperworthAnika Therapeutics market cap ANIK
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $286.7M
- Highest close in our data
- $1B
- Oct 2019
Anika Therapeutics is worth $286.7M at the close on Oct 23, 2026, at $21.42 a share.
That is up 99% over the last year and down 52% over five years.
Its highest close in our data was $1B in Oct 2019.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $286.7M | $133.1M | $291.5M | +108% |
| 2025 | $137.7M | $116.9M | $261.6M | −42% |
| 2024 | $237.8M | $237.8M | $413.7M | −28% |
| 2023 | $331.8M | $253.3M | $469M | −23% |
| 2022 | $432.4M | $305.1M | $496M | −16% |
| 2021 | $517.3M | $492.4M | $671.4M | −20% |
| 2020 | $643.3M | $364.7M | $737.4M | −15% |
| 2019 | $753.9M | $418.1M | $1B | +66% |
| 2018 | $453.9M | $429.6M | $993.6M | −43% |
| 2017 | $790.4M | $620M | $876.7M | +10% |
| 2016 | $716M | $537.5M | $777.6M | +28% |
| 2015 | $558.6M | $465.6M | $638.9M | −1% |
| 2014 | $566.2M | $432.2M | $720.9M | +12% |
| 2013 | $507.3M | $142.4M | $507.3M | +283% |
| 2012 | $132.6M | $126.8M | $230.7M | −1% |
| 2011 | $133.5M | $74M | $133.5M | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| ANIKAnika Therapeutics | $286.7M |
| INFUInfuSystem | $277.6M |
| UTMDUtah Medical Products | $236.3M |
| EMBCEmbecta | $380.2M |
| PDEXPro DEX | $199.3M |
| TCMDTactile Systems Technology | $535.5M |
| MDXGMimedx | $569.9M |
| MOVMovado | $701.9M |
| KEQUKewaunee Scientific | $94.9M |
| IRMDIradimed | $1.1B |
| STAAStaar Surgical | $1.1B |
| Peer median | $457.8M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.